

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

## **VOLUNTARY ANNOUNCEMENT FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) received a notification from Mr. Yan ZHOU (chairman of the Board, executive director, chief executive officer and controlling shareholder of the Company) that during the period from January 12, 2024 to April 15, 2024, Mr. Yan ZHOU further acquired additional H shares of the Company through the open market (the “**Acquisition of H Shares**”). From November 14, 2023 to April 15, 2024, Mr. Yan ZHOU has continuously acquired additional H Shares of the Company in an aggregate amount of HK\$10,420,212.00 with his own funds through the open market and he does not rule out the possibility of further increases in his shareholding in the Company as and when appropriate.

**As of the date of this announcement, the Company’s operations, financial position and sales of existing products are all normal, and the research and development of pipeline vaccine candidates are progressing as planned. The Board is of the view that Mr. Yan ZHOU’s multiple consecutive increases in the shareholding of the Company with his own funds represent his judgment based on the intrinsic value and growth potential of the Company, which demonstrates his confidence in and recognition of the future development of the Company and is conducive to the realization of the Company’s long-term strategic layout.**

After the Acquisition of H Shares and as at the date of this announcement, the Company still satisfies the requirement of maintaining a sufficient public float under Rule 8.08 of the Listing Rules. The Acquisition of H Shares has not triggered any obligation to make a mandatory offer under the Code on Takeovers and Mergers. The Acquisition of H Shares has not resulted in any change in control in the Company.

The shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and Chief Executive Officer*

Hong Kong, April 18, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*